MA50038A - Anticorps anti-pd-l1 de et son utilisation - Google Patents

Anticorps anti-pd-l1 de et son utilisation

Info

Publication number: MA50038A
Authority: MA; Morocco
Prior art keywords: antibodies
Prior art date: 2017-04-18

Application number

MA050038A

Other languages

English (en)

Inventor

Shorena Archuadze

Sergei Barbashov

Vasily Ignatiev

Yan Lavrovsky

Alexey Repik

Mikhail Samsonov

Ting Xu

Original Assignee

R Pharm Overseas Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-18

Filing date

2018-04-18

Publication date

2020-07-08

2018-04-18 Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc

2020-07-08 Publication of MA50038A publication Critical patent/MA50038A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

MA050038A 2017-04-18 2018-04-18 Anticorps anti-pd-l1 de et son utilisation MA50038A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2017028206		2017-04-18

Publications (1)

Publication Number	Publication Date
MA50038A true MA50038A (fr)	2020-07-08

Family

ID=63856823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050038A MA50038A (fr)	2017-04-18	2018-04-18	Anticorps anti-pd-l1 de et son utilisation

Country Status (17)

Country	Link
US (1)	US20210115143A1 (fr)
EP (1)	EP3612565A4 (fr)
JP (2)	JP2020517239A (fr)
KR (1)	KR102323960B1 (fr)
CN (1)	CN110856446A (fr)
AU (1)	AU2018256392B2 (fr)
BR (1)	BR112019021828B1 (fr)
CA (1)	CA3059447A1 (fr)
CL (1)	CL2019002953A1 (fr)
CO (1)	CO2019012118A2 (fr)
EA (1)	EA201900443A1 (fr)
MA (1)	MA50038A (fr)
MX (1)	MX2019012461A (fr)
MY (1)	MY199319A (fr)
PH (1)	PH12019502302A1 (fr)
SG (1)	SG11201909041SA (fr)
WO (1)	WO2018195226A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9139653B1 (en)	2015-04-30	2015-09-22	Kymab Limited	Anti-human OX40L antibodies and methods of treatment
KR102379464B1 (ko)	2016-06-20	2022-03-29	키맵 리미티드	항-pd-l1 항체
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
WO2018083248A1 (fr)	2016-11-03	2018-05-11	Kymab Limited	Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
JP7497351B2 (ja) *	2018-11-13	2024-06-10	コンパスセラピューティクスリミテッドライアビリティカンパニー	チェックポイント分子に対する多重特異性結合性構築物およびその使用
CN113646330A (zh)	2018-11-14	2021-11-12	鲁比克治疗股份有限公司	工程化cd25多肽及其用途
CA3120096A1 (fr)	2018-11-14	2020-05-22	Rubryc Therapeutics, Inc.	Anticorps anti-cd25
CN109929037B (zh)	2019-04-01	2023-03-17	华博生物医药技术（上海）有限公司	针对程序性死亡配体的结合物及其应用
JP7302010B2 (ja) *	2019-04-11	2023-07-03	スクリップスコリアアンチボディインスティチュート	プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
SG11202103000WA (en) *	2019-04-26	2021-04-29	I Mab Biopharma Us Ltd	Human pd-l1 antibodies
US20210403568A1 (en) *	2020-06-29	2021-12-30	Cai Gu Huang	Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CA3187850A1 (fr)	2020-08-04	2022-02-10	Bryan Glaser	Agents de liaison a pd-l1 et leurs utilisations
MX2024001877A (es)	2021-08-10	2024-02-28	Kymab Ltd	Tratamiento de dermatitis atopica.
WO2023046113A1 (fr) *	2021-09-24	2023-03-30	广东菲鹏制药股份有限公司	Anticorps humanisé anti-pd-l1 humain ou fragment de liaison à l'antigène de celui-ci, et son utilisation
US20240294651A1 (en)	2023-01-30	2024-09-05	Kymab Limited	Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE454137T1 (de) *	2001-07-25	2010-01-15	Facet Biotech Corp	Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MX356367B (es) *	2008-12-09	2018-05-25	Genentech Inc	Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US10202454B2 (en) *	2013-10-25	2019-02-12	Dana-Farber Cancer Institute, Inc.	Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015103602A1 (fr) *	2014-01-06	2015-07-09	The Trustees Of The University Of Pennsylvania	Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunothérapie
CA3265373A1 (fr) *	2014-02-20	2025-10-30	H. Lundbeck A/S	Anticorps anti-acth et leur utilisation
CN105777906B (zh) *	2014-12-19	2019-04-23	苏州丁孚靶点生物技术有限公司	抗pd-l1全人抗体及其应用
MA42971A (fr) *	2015-03-13	2018-08-15	Cytomx Therapeutics Inc	Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP7011657B2 (ja) *	2016-10-30	2022-02-10	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｐｄ－ｌ１抗体および変異型

2018
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 CA CA3059447A patent/CA3059447A1/fr active Pending
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/fr not_active Withdrawn
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko not_active Expired - Fee Related
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/fr not_active Ceased
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt not_active IP Right Cessation
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending

Also Published As

Publication number	Publication date
CO2019012118A2 (es)	2020-04-01
WO2018195226A1 (fr)	2018-10-25
CL2019002953A1 (es)	2020-01-10
US20210115143A1 (en)	2021-04-22
EP3612565A1 (fr)	2020-02-26
CA3059447A1 (fr)	2018-10-25
SG11201909041SA (en)	2019-11-28
JP2023025003A (ja)	2023-02-21
BR112019021828B1 (pt)	2022-09-20
MY199319A (en)	2023-10-24
EA201900443A1 (ru)	2020-03-06
EP3612565A4 (fr)	2021-06-16
PH12019502302A1 (en)	2020-09-21
MX2019012461A (es)	2019-12-11
AU2018256392B2 (en)	2024-05-16
BR112019021828A2 (pt)	2020-03-24
KR20190141169A (ko)	2019-12-23
JP2020517239A (ja)	2020-06-18
AU2018256392A1 (en)	2019-10-17
KR102323960B1 (ko)	2021-11-10
CN110856446A (zh)	2020-02-28

Publication	Publication Date	Title
EP3904386A4 (fr)	2022-09-07	Anticorps et son utilisation
EP3612565A4 (fr)	2021-06-16	Anticorps anti-pd-l1 de et son utilisation
EP3575318A4 (fr)	2021-04-14	Anticorps anti-pd-1 et son utilisation
EP3802612A4 (fr)	2022-03-23	Anticorps anti-b7-h3 et son utilisation
EP3797124A4 (fr)	2022-03-23	Anticorps anti-ro1 et son utilisation
EP3887403A4 (fr)	2022-08-31	Anticorps anti-4-1bb et son utilisation
EP3604338A4 (fr)	2021-04-28	Anticorps anti-ox40 et utilisation correspondante
EP3587453A4 (fr)	2021-07-07	Anticorps anti-pd-l1 et son application
EP3907240A4 (fr)	2023-02-22	Anticorps anti-tnfr2 et son utilisation
EP3546482A4 (fr)	2020-10-21	Anticorps anti-cd47 et son utilisation
EP3626825A4 (fr)	2021-02-17	Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3599249A4 (fr)	2021-04-21	Conjugué anticorps anti-5t4-médicament et son utilisation
EP3572427A4 (fr)	2021-04-28	Anticorps ciblant bcma et son utilisation
EP3523332A4 (fr)	2019-10-09	Anticorps anti-4-1 bb humain et son utilisation
EP3819313A4 (fr)	2021-09-01	Anticorps bispécifique et son utilisation
EP3400243A4 (fr)	2019-09-25	Anticorps anti-pd-l1 et utilisations associées
EP3684812A4 (fr)	2021-09-08	Anticorps anti-ctla4 et utilisations associées
MA47311A (fr)	2019-11-27	Anticorps anti-tgf-bêta et leur utilisation
EP3473649A4 (fr)	2020-06-17	Anticorps monoclonal anti-cd47 et application correspondante
EP3589660A4 (fr)	2021-04-07	Anticorps anti-pd-l1 et utilisations associées
MA52284A (fr)	2021-02-24	Anticorps anti-hla-g et leur utilisation
EP4082570A4 (fr)	2023-09-13	Anticorps anti-ctla-4 et son utilisation
EP3571231A4 (fr)	2020-12-02	Anticorps anti-pd-1 et leurs utilisations
EP3363816A4 (fr)	2019-10-09	Anticorps anti-ox40 et son application
EP3630844A4 (fr)	2021-03-03	Nouvel anticorps anti-c-met et son utilisation